EP3856195A4 - Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 - Google Patents
Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 Download PDFInfo
- Publication number
- EP3856195A4 EP3856195A4 EP19867321.2A EP19867321A EP3856195A4 EP 3856195 A4 EP3856195 A4 EP 3856195A4 EP 19867321 A EP19867321 A EP 19867321A EP 3856195 A4 EP3856195 A4 EP 3856195A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- ccr3
- inhibitors
- compositions
- methods
- treating aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000032683 aging Effects 0.000 title 1
- 230000006735 deficit Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737017P | 2018-09-26 | 2018-09-26 | |
PCT/US2019/052995 WO2020069008A1 (fr) | 2018-09-26 | 2019-09-25 | Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3856195A1 EP3856195A1 (fr) | 2021-08-04 |
EP3856195A4 true EP3856195A4 (fr) | 2022-06-22 |
Family
ID=69953286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19867321.2A Pending EP3856195A4 (fr) | 2018-09-26 | 2019-09-25 | Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3856195A4 (fr) |
JP (2) | JP7528065B2 (fr) |
KR (1) | KR20210065950A (fr) |
CN (1) | CN112789044A (fr) |
AU (1) | AU2019346456A1 (fr) |
BR (1) | BR112021004938A2 (fr) |
CA (1) | CA3111433A1 (fr) |
CL (1) | CL2021000724A1 (fr) |
CO (1) | CO2021003713A2 (fr) |
EA (1) | EA202190463A1 (fr) |
IL (1) | IL281578A (fr) |
MA (1) | MA53743A (fr) |
MX (1) | MX2021002967A (fr) |
SG (1) | SG11202102105VA (fr) |
TW (1) | TW202027752A (fr) |
WO (1) | WO2020069008A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005090330A1 (fr) * | 2004-03-22 | 2005-09-29 | Astrazeneca Ab | Derives de n-piperidine utilises en tant que modulateurs ccr3 |
US20130266646A1 (en) * | 2012-04-04 | 2013-10-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising ccr3 antagonists |
US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
WO2018187503A1 (fr) * | 2017-04-05 | 2018-10-11 | Alkahest, Inc. | Méthodes et compositions destinées à traiter des troubles associés au vieillissement à l'aide d'inhibiteurs de ccr3 |
WO2018187473A1 (fr) * | 2017-04-05 | 2018-10-11 | Alkahest Inc. | Méthodes et compositions pour traiter une maladie associée à la rétine à l'aide d'inhibiteurs de ccr3 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1996551A2 (fr) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Derives de piperidine, leur procede de preparation, leur utilisation comme agents therapeutiques et compositions pharmaceutiques les contenant |
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
AR076362A1 (es) | 2009-04-22 | 2011-06-08 | Axikin Pharmaceuticals Inc | Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras. |
UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
-
2019
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/fr active Pending
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko unknown
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 CA CA3111433A patent/CA3111433A1/fr active Pending
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/ja active Active
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/fr active Application Filing
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
-
2024
- 2024-07-24 JP JP2024118649A patent/JP2024153742A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005090330A1 (fr) * | 2004-03-22 | 2005-09-29 | Astrazeneca Ab | Derives de n-piperidine utilises en tant que modulateurs ccr3 |
US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US20130266646A1 (en) * | 2012-04-04 | 2013-10-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising ccr3 antagonists |
WO2018187503A1 (fr) * | 2017-04-05 | 2018-10-11 | Alkahest, Inc. | Méthodes et compositions destinées à traiter des troubles associés au vieillissement à l'aide d'inhibiteurs de ccr3 |
WO2018187473A1 (fr) * | 2017-04-05 | 2018-10-11 | Alkahest Inc. | Méthodes et compositions pour traiter une maladie associée à la rétine à l'aide d'inhibiteurs de ccr3 |
Non-Patent Citations (2)
Title |
---|
REGE S ET AL: "Abstracts from the 13th International Conference on Cerebral Vascular Biology (CVB 2019)", FLUIDS AND BARRIERS OF THE CNS, vol. 16, no. S1, 1 June 2019 (2019-06-01), XP093106172, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12987-019-0135-8/fulltext.html> DOI: 10.1186/s12987-019-0135-8 * |
See also references of WO2020069008A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN112789044A (zh) | 2021-05-11 |
AU2019346456A1 (en) | 2021-04-15 |
JP2024153742A (ja) | 2024-10-29 |
CO2021003713A2 (es) | 2021-04-08 |
BR112021004938A2 (pt) | 2021-06-01 |
MX2021002967A (es) | 2021-08-11 |
MA53743A (fr) | 2022-01-05 |
WO2020069008A1 (fr) | 2020-04-02 |
CL2021000724A1 (es) | 2021-10-15 |
TW202027752A (zh) | 2020-08-01 |
SG11202102105VA (en) | 2021-04-29 |
JP2022502441A (ja) | 2022-01-11 |
EP3856195A1 (fr) | 2021-08-04 |
JP7528065B2 (ja) | 2024-08-05 |
EA202190463A1 (ru) | 2021-06-29 |
IL281578A (en) | 2021-05-31 |
CA3111433A1 (fr) | 2020-04-02 |
KR20210065950A (ko) | 2021-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3606525A4 (fr) | Méthodes et compositions destinées à traiter des troubles associés au vieillissement à l'aide d'inhibiteurs de ccr3 | |
EP3823673A4 (fr) | Compositions anti-cd112r et procédés | |
EP3924490A4 (fr) | Procédés de traitement de la cholestase | |
EP3297702A4 (fr) | Méthodes et compositions permettant de traiter des troubles associés au vieillissement | |
EP3735325A4 (fr) | Compositions et procédés de traitement de surface | |
EP3852608A4 (fr) | Compositions et méthodes destinées à traiter le glaucome | |
EP3307296A4 (fr) | Procédés et compositions pour traiter des états associés au vieillissement | |
IL290840A (en) | Preparations and methods for altering cd123 | |
EP3931336A4 (fr) | Compositions et procédés de traitement de laminopathies | |
EP3687524A4 (fr) | Compositions et méthodes de traitement de troubles ophtalmiques | |
EP3790557A4 (fr) | Compositions et méthodes pour améliorer la distorsion de brin | |
EP3844500A4 (fr) | Compositions de rp182 et procédés | |
EP3801478A4 (fr) | Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie | |
EP3830196A4 (fr) | Compositions et procédés de traitement de surface | |
EP3618850A4 (fr) | Compositions et méthodes de traitement de pathologies oculaires | |
EP3801534A4 (fr) | Compositions et procédés pour augmenter l'exposition au plasma de tétrahydrobioptérine | |
EP3752161A4 (fr) | Méthodes de traitement de la fibrose | |
EP3755328A4 (fr) | Compositions et méthodes de traitement du prurit | |
EP3801620A4 (fr) | Compositions et méthodes de traitement de la pancréatite | |
EP3990394A4 (fr) | Compositions et procédés de traitement des eaux usées | |
EP3870210A4 (fr) | Compositions et procédés de traitement ou de prévention de la fibrose | |
EP3883995A4 (fr) | Compositions polymères expansées par extrusion et procédés de fabrication de compositions polymères expansées par extrusion | |
EP3856195A4 (fr) | Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 | |
EP3921286A4 (fr) | Procédés et compositions pour le traitement d'eau produite | |
EP3917320A4 (fr) | Compositions et procédés bactéricides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210325 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAV | Requested validation state of the european patent: fee paid |
Extension state: MD Effective date: 20210325 Extension state: MA Effective date: 20210325 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031535000 Ipc: A61K0031454500 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220520 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20220516BHEP Ipc: A61P 25/16 20060101ALI20220516BHEP Ipc: A61P 25/00 20060101ALI20220516BHEP Ipc: A61K 9/00 20060101ALI20220516BHEP Ipc: A61K 47/00 20060101ALI20220516BHEP Ipc: A61K 33/00 20060101ALI20220516BHEP Ipc: A61K 31/00 20060101ALI20220516BHEP Ipc: A61P 1/00 20060101ALI20220516BHEP Ipc: A61K 31/4545 20060101AFI20220516BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231201 |